XAIR News and Press, Beyond Air Inc. From 06/28/22

Beyond Air press release (NASDAQ:XAIR): FY GAAP EPS of -$1.68 misses by $0.47. As of March 31, 2022, the Company had cash and cash equivalents of $80.2 million. Shares +35.81%. For further details see: Beyond Air GAAP EPS of -$1.68 misses by $0.47

LungFit ® PH received FDA approval for the treatment of term and near-term neonates with hypoxic respiratory failure on June 28, 2022 and the first phase of U.S. commercial launch has begun Presented positive data for high-concentration nitric oxide (NO) with LungFit ...

First and only nitric oxide generator and delivery system indicated for the treatment of term and near-term neonates with hypoxic respiratory failure that uses ambient air to provide unlimited, on-demand nitric oxide Eliminates the need for traditional nitric oxide tanks f...

AEMD, OTCPK:ANCUF, AVAV, OTC:OIBZQ, PRGS, XAIR For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings after Tuesday's close

ADBE, XAIR For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings after Thursday's close

Sidus Space (SIDU) +86% on NASA’s $3.5 Billion exploration extravehicular activity services contract. Evoke Pharma (EVOK) +68% on approval for nasal spray Gimoti being added to Florida's Medicaid program Boxed (BOXD) +33%. ACADIA Pharmaceuticals (ACAD) +29% as FDA posts ...

GARDEN CITY, New York, June 14, 2022 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infection...

My " three stocks to avoid " column last week was a mixed bag. The three stocks I thought were going to move lower for the week -- Hooker Furnishings , Stitch Fix , and ChargePoint -- finished up 1%, down 28%, and down 1%, respectively, averaging out to a 9.3% decline. T...

Dr. Monson is a board-certified radiation oncologist and brings over 25 years of clinical oncology experience to Beyond Cancer. Dr. Monson is a founding partner and President of California Cancer Associates for Research & Excellence (cCARE), the largest private oncology practi...

A total of 2,323 inhalations have been self-administered at home to date with no treatment related discontinuations reported and overall high treatment compliance All subjects have successfully titrated to receive the target 250 ppm NO regimen at home LungFit® GO is...